TSO3 new generation sterilizer exhibited for the first time at major tradeshow under the 3M brand

	    <<
	    Ticker: TSX - TOS
	    Shares Outstanding: 57,896,123
	    >>

	    QUEBEC CITY, March 16 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS), an
innovator in sterilization technology for medical devices in healthcare
settings using ozone, announced today that its new generation STERIZONE(R)
Sterilization System, is being exhibited in the 3M(TM)booth under the 3M(TM)
brand Optreoz(TM)125-Z Sterilizer at the Association of Perioperative
Registered Nurses (AORN) 57th Annual Congress held from March 13 to 18 in
Denver, Colorado.
	    AORN's annual Congress
(http://www.aorn.org/ExhibitorsAndAdvertisers/AnnualCongress/) is the world's
premier educational event and tradeshow addressing the needs for the Operating
Room (OR) suite, including sterile reprocessing. Nearly 7,000 perioperative
nurses and nurse managers, representing over 2,000 hospitals and facilities,
gather each year at this event to keep up-to-date with the latest in
recommended practices, hot topics, products, and services. 80% of all Congress
attendees have influence over purchasing in their facilities.
	    "It is a very exciting time for TSO3. Seeing our product presented at
AORN in the 3M(TM) booth under the 3M(TM) brand attests to the importance of
recent enhancements in both cycle development and distribution strength", said
R. M. (Ric) Rumble, CEO at TSO3.
	    On December 16 2009, TSO3 announced a global channel partnership with
3M(TM) Infection Prevention Division, for the exclusive supply and
distribution of its new generation sterilizer through 3M's worldwide
operations under the 3M(TM) brand, as regulatory clearances are received.
	    Also in December 2009, TSO3 filed for regulatory clearances on the new
generation product in Canada, Europe and the United States. TSO3 has now
received authorizations from both Health Canada and the notification from the
European Notified Body (CE Mark), allowing the sale of the product in Canada
and in the European Union. The product is not available for sale in the United
States. A 510k has been submitted and is currently under review.
	    The new generation sterilizer offers three sterilization cycles in a
single unit and is able to quickly and gently sterilize packaged simple and
complex medical devices. These devices range from general surgical
instruments, to short and long, rigid and flexible endoscopes, including
complex multi-channel devices.

	    About AORN

	    AORN is the global leader in promoting excellence in perioperative
nursing practice, supporting registered nurses in achieving optimal outcomes
for patients undergoing surgical and other invasive procedures. The
Association is composed of approximately 40,000 perioperative registered
nurses in the United States and abroad. Perioperative nurses are defined as
"those who provide, manage, teach, and study the care of patients undergoing
operative or other invasive procedures."
	    AORN was formally organized between 1949 and 1954. The first national
conference was held in 1954. The organization was formally incorporated as
AORN, Inc, in 1960. The Headquarters office was relocated to Denver in 1969.
	    For more information on AORN, visit the association's Web Site at:
http://www.aorn.org

	    About TSO3

	    TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology with high commercial potential. TSO3 designs products for sterile
processing areas in the hospital environment and offers an advantageous
replacement solutions to other low temperature sterilization processes
currently used in hospitals.
	    For more information about TSO3, visit the Company's Web site at
www.tso3.com

	    The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.

	    The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.

	    /NOTE TO PHOTO EDITORS: A photo accompanying this release is available at
http://photos.newswire.ca. Images are free to accredited members of the media/





-30-

	    /For further information: Caroline Côté, Director, Corporate
Communications and Investor Relations, (418) 651-0003, Ext. 237,
ccote@tso3.com; Source: TSO(3) Inc./